Merrimack Pharma (MACK) Reports Q4 Loss of $0.89

Note: EPS may not be comparable

Merrimack Pharma (NASDAQ: MACK) reported Q4 EPS of ($0.89), versus ($0.28) reported last year. Revenue for the quarter came in at $0 versus the consensus estimate of $11 million.

• Net loss attributable to Merrimack's continuing operations for the three months ended December 31, 2017 was $11.8 million, or $0.89 per share, compared to a net loss attributable to Merrimack\'s continuing operations of $40.1 million, or $2.93 per share, for the three months ended December 31, 2016.

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
• Interactive Strength reports record Q2 results, raises Q3 guidance